Aureus Pharma Licenses AurSCOPE® GPCR to Serono
News Apr 12, 2006
Aureus Pharma has announced that Serono has become a customer of its AurSCOPE GPCR knowledge database.
In this multi-year agreement, scientists at Serono Pharmaceutical Research Institute in Geneva will have access to both the AurSCOPE knowledge database and AurQUEST, a web application designed to query Aureus’ knowledge bases.
AurSCOPE GPCR is comprised of detailed biological activity quantitative data from patents and journals form.
G-Protein Coupled Receptors are a major interest for the pharmaceutical industry as they are targets in a number of therapeutic areas including CNS, cardiovascular, metabolic disease, obesity, oncology and others.
"Aureus Pharma’s knowledgebase on GPCR will provide Serono researcher’s with high quality quantitative data which will complement our in-house experimental platform," commented Serono’s Dr. Serge Halazy, Head of Research, Switzerland.
"We are very pleased to have Serono join our growing list of customers in the pharmaceutical and biotechnology industry," said Dr. Andre Michel, CEO of Aureus Pharma.
"Having access to the high quality data in AurSCOPE GCPR will aid researchers in the discovery of new GPCR targeted drugs."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE